ABT-414 will be administered by intravenous infusion
- Participant must have epidermal growth factor receptor (EGFR) amplification or EGFRvIII mutation.
- Health Care Provider (HCP) must have prior clinical trial experience with ABT-414.
- The participant must not be eligible for an ABT-414 clinical trial.
- Pediatric participants may be evaluated on a case by case basis
ABBVIE CALL CENTER
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.